<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03843112</url>
  </required_header>
  <id_info>
    <org_study_id>REG-076-2018</org_study_id>
    <nct_id>NCT03843112</nct_id>
  </id_info>
  <brief_title>Modulating the Vaginal Microbiome After Implantation Failure</brief_title>
  <official_title>Modulating the Vaginal Microbiome After Implantation Failure A Randomized Placebo Controlled Study of Vaginal Lactobacilli Supplements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARTPred</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bifodan A/S</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaginal microbiome has in studies shown a link with the outcome of fertility treatment. The
      investigators wish to determine if it is possible to change an unfavorable vaginal microbiome
      using lactobacilli loaded vaginal supplements.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised placebo controlled, double blinded study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, investigator, care providers and outcome assessors are all blinded until the end of inclusion af the last subject.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vaginal microbiome after intervention</measure>
    <time_frame>2 months</time_frame>
    <description>The investigators wish to determine if the vaginal microbiome will stay changed one month after intervention. The change in vaginal microbiome will be measured with ARTPreds diagnostic test, after intervention and again one month later. The test divides the vaginal microbiome into three categories, low, medium and high. A change in vaginal microbiome is defined by a shift from low to medium or high, or a shift from medium to high.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Implantation Failure</condition>
  <condition>Infertility, Female</condition>
  <condition>Vaginal Flora Imbalance</condition>
  <arm_group>
    <arm_group_label>Vivag Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vivag Plus</intervention_name>
    <description>Contains two lactobacilli strains; l. gasseri and l. rhamnosus</description>
    <arm_group_label>Vivag Plus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Cap</intervention_name>
    <description>Vaginal supplements</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo vaginal capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unfavorable vaginal microbiome using ARTPreds test

          -  non-smoker

        Exclusion Criteria:

          -  use of oral antibiotics oral probiotics between diagnosis and inclusion in the study

          -  pregnancy at inclusion

          -  allergy towards study drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nick Macklon, Prof.</last_name>
    <phone>004553621645</phone>
    <email>nism@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Malene Hviid, M.D</last_name>
    <email>mahv@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fertilitetsklinikken, Region Sjælland</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrine Birch Petersen, PhD. MD</last_name>
      <phone>24645414</phone>
      <phone_ext>0045</phone_ext>
      <email>kbpt@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zealand University Hospital</investigator_affiliation>
    <investigator_full_name>Nicholas Macklon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Infertility, female</keyword>
  <keyword>Vaginal microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03843112/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

